Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment ; volume:6 ; number:3 ; day:26 ; month:4 ; year:2004 ; pages:1-9 ; date:6.2004
Arthritis Research & Therapy ; 6, Heft 3 (26.4.2004), 1-9, 6.2004
- Urheber
-
Bobbio-Pallavicini, Francesca
- Beteiligte Personen und Organisationen
-
Alpini, Claudia
Caporali, Roberto
Avalle, Stefano
Bugatti, Serena
Montecucco, Carlomaurizio
SpringerLink (Online service)
- DOI
-
10.1186/ar1173
- URN
-
urn:nbn:de:1111-20160503796
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bobbio-Pallavicini, Francesca
- Alpini, Claudia
- Caporali, Roberto
- Avalle, Stefano
- Bugatti, Serena
- Montecucco, Carlomaurizio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab
Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes
Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report
Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis
In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response
Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab
Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes
Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report
Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis
In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response
Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab
Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes
Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report
Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis